Articles On Immutep (ASX:IMM)
Title | Source | Codes | Date |
---|---|---|---|
CLOSING BELL: Shopping centres, diggers and banks drive local market 0.65% against overseas tide
ASX 200 benchmark climbs 0.65% despite a sour lead-in from Wall Street and Europe. Real Estate sector banks solid wins after shopping centres put on a big day. Forrestania Resources hits 162% on thick pegmatite news, but the ASX has asked... |
Stockhead | IMM | 1 year ago |
Immutep (ASX:IMM) – Webinar Presentation
Marc Voigt – Executive Director & CEO – Immutep (ASX:IMM) is a clinical-stage biotechnology company at the forefront of developing novel LAG-3 immunotherapy for cancer and autoimmune diseases. |
ShareCafe | IMM | 1 year ago |
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines
Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month The world is anticipating a “game changer” as Brisba... |
Stockhead | IMM | 1 year ago |
Immutep granted US patent
20 Jun 2023 - Immutep Limited (ASX:IMM), a clinical-stage biotechnology company focusing on LAG-3 immunotherapies for cancer and autoimmune diseases, has received a new patent from… |
FNN | IMM | 1 year ago |
CLOSING BELL: Local markets climbed 0.86% today, but those sods at the RBA want you out of a job.
The ASX 200 climbed 0.86% today, after the RBA said it wants you all to get fired. Energy stocks climb 1.94% after I dared to turn my heater on this morning. Brightstar is thiiiis close to actual gold production, up 30% today as a result.... |
Stockhead | IMM | 1 year ago |
2 ASX lithium shares surging 9% on big news
A couple of ASX lithium shares have been catching the eye on Tuesday with some strong gains. Letâs take a look and see whatâs getting investors excited today: Leo Lithium Ltd (ASX: LLL) The Leo Lithium share price is up 9% to $1.17. Th... |
Motley Fool | IMM | 1 year ago |
ASX Health Stocks: Sub $50m market cap Austco nabs $7.4m contract, the biggest in its history
Austco Healthcare wins St Paul’s Hospital in Canada worth $7.4m Next Science announced a new CEO AVITA Medical and Genetic Signatures announce new CFOs Digital health company Austco Healthcare (ASX:AHC) surged by as high as 30% this mor... |
Stockhead | IMM | 1 year ago |
Why Australian Ethical, Delta Lithium, Emeco, and Navigator Global are racing higher
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record another gain. The benchmark index is currently up 0.25% to 7,180 points. Four ASX shares that are climbing more than most today are listed below. Hereâs why... |
Motley Fool | IMM | 1 year ago |
2 ASX shares I think could double in 3 years
I believe that the two ASX shares Iâm going to write about in this article have the potential to deliver total returns of over 100% in the next three years. While small businesses naturally have more room to grow compared to large busine... |
Motley Fool | IMM | 1 year ago |
The Ethical Investor: Why Starpharma and these ASX biotechs could stop the next infectious disease outbreak
The infectious diseases space is one area that could be interesting for ethical investors An ASX company that already has a product in the market is Starpharma Stockhead reached out to Starpharma CEO, Jackie Fairley Throughout history,... |
Stockhead | IMM | 1 year ago |
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends
Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week When we talk about dividend-paying hea... |
Stockhead | IMM | 1 year ago |
This ASX All Ords share fell off a cliff in May, and directors are buying the dip
ASX All Ords retail share Universal Store Holdings Ltd (ASX: UNI) crashed by almost 25% in just two weeks and three company directors have enthusiastically bought the dip. One took a ‘go hard or go home’ approach and ploughed more than $1... |
Motley Fool | IMM | 1 year ago |
2 ASX 200 shares having a shocker that you must buy right now
All stocks, no matter how well they perform in the long run, will have short-term dips. That’s why it’s imperative to not get distracted by these fluctuations. In fact, if the quality of the business’ future prospects hasn’t changed then... |
Motley Fool | IMM | 1 year ago |
Why I’m backing this beaten-up ASX All Ords share for a big 3-year turnaround
The Adairs Ltd (ASX: ADH) share price suffered a big sell-off last week â it fell around 15% on Friday. Itâs down 28% from 22 May 2023 and it has dropped 45% from 1 February 2023. The ASX All Ordinaries Index (ASX: XAO) share has been... |
Motley Fool | IMM | 1 year ago |
These excellent ASX growth shares could be buys
If you have room for some new portfolio additions in June, then it could be worth considering the three ASX growth shares listed below. Hereâs what you need to know about these buy-rated shares: Aristocrat Leisure Limited (ASX: ALL) The... |
Motley Fool | IMM | 1 year ago |
Fundies pile into Immutep $80m raise
Several new health-focused funds joined the biotech’s register including Platinum. |
AFR | IMM | 1 year ago |
Buy these top ASX dividend stocks with 5% yields: brokers
If youâre searching for a passive income boost, then you may want to check out the ASX dividend stocks listed below. Analysts have named these dividend stocks as buys and tipped them to provide very large yields in the near term. Hereâ... |
Motley Fool | IMM | 1 year ago |
Why are ASX retail shares taking a hit on Friday?
ASX retail shares are falling amid news today of a 5.75% hike to the minimum wage and concern among investors about the rising cost of living now affecting retail sales in 2023. Earlier today the Fair Work Commission announced a 5.75% bum... |
Motley Fool | IMM | 1 year ago |
Why Adairs, Bubs, Immutep, and Lovisa shares are dropping today
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on track to end the week on a positive note. At the time of writing, the benchmark index is up 0.25% to 7,129.3 points. Four ASX shares that have failed to follow the market high... |
Motley Fool | IMM | 1 year ago |
What’s going on with the Bubs share price today?
The Bubs Australia Ltd (ASX: BUB) share price is falling on more disappointing sales data from China and amid a move that could see four board members canned. Bubs founder and former CEO Kristy Carr is leading a group of shareholders calli... |
Motley Fool | IMM | 1 year ago |
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough
Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May There are clear signs the biotech sector is springing back to life after a disappointing 2... |
Stockhead | IMM | 1 year ago |
CLOSING BELL: A massive win for Zelira’s new pain drug has polished an absolute turd of a day
The ASX 200 fell 1.37%, and the bad news kept piling up all day Inflation data knee-capped the market mid-morning, because rate hikes are on the way Two Small Caps hit triple-figure home runs today, which is kinda amazing Welp… that was... |
Stockhead | IMM | 1 year ago |
Immutep in $80m raise; Bells, Jefferies and Wilsons on ticket
The immunotherapy biotech had brokers Bell Potter, Jefferies and Wilsons in its corner on Wednesday. |
AFR | IMM | 1 year ago |
Why has this ASX 300 lithium share soared 29% in 2 days?
The S&P/ASX 300 (ASX: XKO) has climbed 0.78% in the last two days, but this ASX 300 lithium share is far outperforming the index. The Leo Lithium Ltd (ASX: LLL) share price is up 29% this trading week and is now at 93.2 cents. In toda... |
Motley Fool | IMM | 1 year ago |
Immutep selects Charles River Laboratories for IMP761’s GLP toxicology study
Immutep (ASX:IMM) has announced it has entered into an agreement under which Charles River will conduct a GLP toxicology study for IMP761. |
BiotechDispatch | IMM | 1 year ago |
ASX lithium share Leo Lithium is leaping 14% higher today. Here’s why
ASX lithium share Leo Lithium Ltd (ASX: LLL) is soaring higher today, up 13.8% in early trade. Shares in the S&P/ASX 300 Index (ASX: XKO) lithium stock closed Friday trading for 72.5 cents. In early trade on Monday, shares are swapping... |
Motley Fool | IMM | 1 year ago |
The Week that Was: May 22-26, 2023
ShareCafeThe Week that Was: May 22-26, 2023 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to do so, her... |
ShareCafe | IMM | 1 year ago |
Brokers name 3 ASX shares to buy now
It has been another busy week for Australiaâs top brokers. This has led to the release of a large number of broker notes. Three broker buy ratings that you might want to know more about are summarised below. Hereâs why brokers think th... |
Motley Fool | IMM | 1 year ago |
ScoPo’s Powerplays: ASX health stocks fall as investors fail to reward good news
ASX health stocks have fallen in the past five days in line with broader markets Volpara Health Technologies reports strong FY23 results, above Morgan’s expectations Pharmaxis reports positive trial results in potential breakthrough treatm... |
Stockhead | IMM | 1 year ago |
Here are the top 10 ASX 200 shares today
The S&P/ASX 200 Index (ASX: XJO) tumbled on Thursday, falling 1.05% to close at 7,138.2 points. The marketâs suffering came amid continued concerns of the United Statesâ rapidly approaching debt ceiling, as my Fool colleague Bernd... |
Motley Fool | IMM | 1 year ago |
TMH Spotlight: market tracks lower while Sandfire Resources (ASX:SFR) produces first copper at Motheo, Botswana
The market is continuing its downward trend for today, with the ASX200 around 0.8 per cent lower in early afternoon trade. Diversified miner, Sandfire Resources (SFR), has produced first copper concentrate at its Motheo copper mine in Bo... |
themarketherald.com.au | IMM | 1 year ago |
Why Adbri, Costa, Delta Lithium, and Immutep shares are racing higher
The S&P/ASX 200 Index (ASX: XJO) has followed Wall Streetâs lead and dropped into the red. At the time of writing, the benchmark index is down 0.85% to 7,151.5. Four ASX shares that are not letting that stop them from rising today... |
Motley Fool | IMM | 1 year ago |
Immutep doses first patient in Phase II/III efti trial to treat metastatic breast cancer
This content is created by Smallcaps Authors. [Author : Imelda Cotton] Biotechnology company Immutep (ASX: IMM) has safely dosed the first patient at a European clinical site for its integrated Phase II/III AIPAC-003 trial to treat metast... |
SmallCaps | IMM | 1 year ago |
Immutep (ASX:IMM) doses first patient in Europe for AIPAC-003 breast cancer trial
Immutep (IMM) enrols and doses its first patient at its European clinical site for its integrated Phase II/III AIPAC-003 trial The trial aims to evaluate the effectiveness of Immutep’s drug candidate, eftilagimod alpha (efti), in combi... |
themarketherald.com.au | IMM | 1 year ago |
Has the Webjet share price peaked or can it keep rising?
The Webjet Limited (ASX: WEB) share price has been on form this week. So much so, the online travel agentâs shares hit a new 52-week high on Wednesday. This means the companyâs shares are now up almost 23% since the start of the year.... |
Motley Fool | IMM | 1 year ago |
ASX Today: Stocks to watch on Thursday
The ASX is expected to fall today on the back of overnight losses across other global markets, namely Europe and the US. Here are some ASX-listed companies to watch out for on Thursday: The first patient in Immutep’s (IMM) AIPAC-003 p... |
themarketherald.com.au | IMM | 1 year ago |
Why are 2 high-flying Aussie billionaires buying this little-known ASX lithium stock?
ASX lithium share Delta Lithium Ltd (ASX: DLI) may not be a household name, but it appears it is attracting interest from billionaire investors. Delta Lithium shares have soared nearly 37% year to date and 44% in the last month. So what... |
Motley Fool | IMM | 1 year ago |
If your super is under $500,000 and you want to retire, you’ll want to read this
The average Australian’s superannuation balance leaves much to be desired for one seeking a comfortable retirement. Fortunately, thereâs a solution. Letâs dive into what anyone hoping to enter retirement without a large super balance c... |
Motley Fool | IMM | 1 year ago |
5 things to watch on the ASX 200 on Thursday
On Wednesday, the S&P/ASX 200 Index (ASX: XJO) was out of form and dropped into the red. The benchmark fell 0.6% to 7,213.8 points. Will the market be able to bounce back from this on Thursday? Here are five things to watch: ASX 200... |
Motley Fool | IMM | 1 year ago |
Check Up: Here’s how diabetes drugs can help you get off the beers and lose weight
Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week Earlier this week, Pfizer surprised the market by say... |
Stockhead | IMM | 1 year ago |
Here are the top 10 ASX 200 shares today
The S&P/ASX 200 Index (ASX: XJO) struggled in Wednesdayâs session, falling 0.63% to close at 7,213.8 points. That was despite a strong performance from the S&P/ASX 200 Energy Index (ASX: XEJ), which lifted 0.7% on the back of ri... |
Motley Fool | IMM | 1 year ago |
Why Immutep, Leo Lithium, Playside, and Webjet shares are storming higher
The S&P/ASX 200 Index (ASX: XJO) has dropped into the red on Wednesday. In afternoon trade, the benchmark index is down 0.5% to 7,221.4 points. Four ASX shares that are not letting that hold them back are listed below. Hereâs why th... |
Motley Fool | IMM | 1 year ago |
ASX Health Stocks: Patrys, Immutep jump after reports show drugs well tolerated
Patry receives positive toxicology reports on PAT-DX1 Immutep says triple combination trial of Efti shows it is well tolerated Clarity Pharma is now advancing to cohort 2 Patrys receives positive report Therapeutic antibody development... |
Stockhead | IMM | 1 year ago |
UBS and Credit Suisse nearing completion of merger: ASX 0.46% lower at noon
ShareCafeUBS and Credit Suisse nearing completion of merger: ASX 0.46% lower at noon by Peter Milios At noon, the S&P/ASX 200 is 0.46 per cent lower at 7,226.50. The SPI futures are pointing to a fall of 28 points. The decline coincid... |
ShareCafe | IMM | 1 year ago |
Stocks of the Hour: Leo Lithium, Empire Energy, Immutep, Cauldron Energy
24 May 2023 - A snapshot of the stocks on the move featuring Leo Lithium (ASX:LLL), Empire Energy (ASX:EEG), Immutep (ASX:IMM) and Cauldron Energy (ASX:CXU). |
FNN | IMM | 1 year ago |
Stocks of the Hour: LLL, EEG, IMM, CXU
ShareCafeStocks of the Hour: LLL, EEG, IMM, CXU Leo Lithium (ASX:LLL) has announced that further drilling at their Goulamina Lithium Project has delivered thick, high grade mineralisation. MD Simon Hay commented, “W... |
ShareCafe | IMM | 1 year ago |
Immutep’s Positive FDA Talks and Strong Survival Data
ShareCafeImmutep’s Positive FDA Talks and Strong Survival Data Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt discusses the significance of recent announcements on the back of a recent surge in trading volume. Paul Sanger:... |
ShareCafe | IMM | 1 year ago |
ScoPo’s Powerplays: ASX health stocks rise, Immutep surges 46pc on trial results
ASX health stocks rise in the past five days in line with broader markets Immutep surges 46% after positive Phase 2 results into lung cancer Avita Medical falls 28% in past five days despite reporting “solid Q1 FY23” results Healthcare a... |
Stockhead | IMM | 1 year ago |
ASX Health Stocks: FDA approves Imugene’s Phase 1 trial; Noxopharm says it can fight skin disease
Immutep gets US FDA clearance to start Phase 1 study Noxopharm says its Sofra platform is effective against inflammatory skin disease Epsilon Healthcare announced a new CEO US FDA approves Imugene’s Phase 1 Immuno-oncology biotech Imug... |
Stockhead | IMM | 1 year ago |
ASX closes 0.52% higher as high iron ore price boosts bellwethers
ShareCafeASX closes 0.52% higher as high iron ore price boosts bellwethers by Peter Milios At the closing bell, the S&P/ASX 200 was 0.52 per cent higher at 7,236.80. Nufarm (ASX:NUF) rallied 14.2 per cent to $6.05 after announcing a 7... |
ShareCafe | IMM | 1 year ago |